A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

NCT00673088 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease
Restless Leg Syndrome

Interventions

DRUG: Ropinirole Hydrochloride

Sponsor

Roxane Laboratories